Literature DB >> 18248757

Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.

Ivan P Nascimento1, Waldely O Dias, Wagner Quintilio, Ana P Christ, Josefina F Moraes, Mary D C Vancetto, Gabriela Ribeiro-Dos-Santos, Isaias Raw, Luciana C C Leite.   

Abstract

The currently used pertussis vaccines are highly efficacious; however, neonates are susceptible to whooping cough up to the sixth month. In agreement, DTP-immunized neonate mice were not protected against intracerebral challenge with Bordetella pertussis. Neonate mice immunized with either DTP or a recombinant-BCG strain expressing the genetically detoxified S1 subunit of pertussis toxin do not show a humoral immune response against PT. On the other hand, rBCG-Pertussis induces higher PT-specific IFN-gamma production and an increase in both IFN-gamma(+) and TNF-alpha(+)-CD4(+)-T cells than the whole cell pertussis vaccine and confers protection against a lethal intracerebral challenge with B. pertussis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18248757     DOI: 10.1016/j.micinf.2007.10.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

Review 1.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

2.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 3.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

4.  Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.

Authors:  Uma Devi K Ranganathan; Michelle H Larsen; John Kim; Steven A Porcelli; William R Jacobs; Glenn J Fennelly
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

5.  Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.

Authors:  Narcís Saubi; Eung-Jun Im; Raquel Fernández-Lloris; Olga Gil; Pere-Joan Cardona; Josep Maria Gatell; Tomáš Hanke; Joan Joseph
Journal:  Clin Dev Immunol       Date:  2011-04-12

6.  The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen.

Authors:  Rosamund Chapman; William R Bourn; Enid Shephard; Helen Stutz; Nicola Douglass; Thandi Mgwebi; Ann Meyers; Nyasha Chin'ombe; Anna-Lise Williamson
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

7.  Optimization of secretion and surface localization of heterologous OVA protein in mycobacteria by using LipY as a carrier.

Authors:  Maroeska J Burggraaf; Louis S Ates; Alexander Speer; Kim van der Kuij; Coen Kuijl; Wilbert Bitter
Journal:  Microb Cell Fact       Date:  2019-03-06       Impact factor: 5.328

8.  A Bivalent Recombinant Mycobacterium bovis BCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4+ T Cell Immune Response.

Authors:  Alex I Kanno; Cibelly Goulart; Luciana C C Leite; Ana C Pagliarone; Ivan P Nascimento
Journal:  Biomed Res Int       Date:  2019-02-28       Impact factor: 3.411

Review 9.  BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.

Authors:  Camila Covián; Ayleen Fernández-Fierro; Angello Retamal-Díaz; Fabián E Díaz; Abel E Vasquez; Margarita K Lay; Claudia A Riedel; Pablo A González; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

Review 10.  Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections.

Authors:  Monica C Gestal; Hannah M Johnson; Eric T Harvill
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.